Back to results
US 10,287,321 B2Granted
Re-directed immunotherapy
AssigneeThe University of Birmingham
InventorsMark Cobbold, David Millar
Life of this patent
Estimating the term…
Abstract
The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
Claims21
An agent for retargeting T cells to solid tumor cells, the agent comprising:
- (i) a targeting moiety that is capable of targeting to the solid tumor cells, wherein the targeting moiety is an antibody or antigen binding fragment thereof that binds a solid tumor antigen;
- and
- (ii) a viral T cell epitope that elicits an existing immune response in the subject and binds to a HLA molecule on the surface of the cancer cell of the human subject and has a HLA matched to the subject,
- (iii) a peptide linker comprising a peptide cleavage site cleavable by a tumor associated protease and
- wherein the linker can be selectively cleaved by the tumor associated protease to release the T cell epitope in the vicinity of, and outside of, the solid tumor cells and wherein the solid tumor is not a lymphoma.
2 more elements
Dependencies are inferred from the claim text.